{
    "clinical_study": {
        "@rank": "63822", 
        "arm_group": {
            "arm_group_label": "ALN-TTRSC", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and\n      exploratory clinical activity of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac\n      Amyloidosis."
        }, 
        "brief_title": "Phase 2 Study to Evaluate ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "TTR-mediated Amyloidosis", 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  TTR cardiac amyloidosis;\n\n          -  Women of child-bearing potential (WOCBP) must have a negative pregnancy test, cannot\n             be breast feeding, and must be willing to use 2 highly effective methods of\n             contraception;\n\n          -  Male subjects agree to use appropriate contraception;\n\n          -  Adequate blood counts, liver, renal and heart function;\n\n          -  Adequate Karnofsky performance status;\n\n          -  Adequate New York Heart Association (NYHA) Classification Score;\n\n          -  Clinically stable on heart medications;\n\n          -  Adequate 6-minute walk test;\n\n          -  Willing to give written informed consent and are willing to comply with the study\n             requirements.\n\n        Exclusion Criteria:\n\n          -  Known human immunodeficiency virus (HIV) positive status or known or suspected\n             systemic bacterial, viral, parasitic, or fungal infection;\n\n          -  Subjects with a history of multiple drug allergies or intolerance to SC injection;\n\n          -  Received an investigational agent other than tafamidis, diflunisal, doxycycline or\n             tauroursodeoxycholic acid, or an investigational device within 30 days prior to first\n             dose of study;\n\n          -  Uncontrolled hypertension, ischemic heart disease or cardiac arrhythmia;\n\n          -  Untreated hypo- or hyperthyroidism;\n\n          -  Prior major organ transplant;\n\n          -  Considered unfit for the study by the Principal Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981837", 
            "org_study_id": "ALN-TTRSC-002"
        }, 
        "intervention": {
            "arm_group_label": "ALN-TTRSC", 
            "intervention_name": "ALN-TTRSC for subcutaneous administration", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "RNAi therapeutic", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02155"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10034"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "UK NW3 2PF"
                    }, 
                    "name": "Clinical Trial Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis", 
        "overall_contact": {
            "last_name": "Alnylam Clinical Trials Hotline. Call for Complete Site List.", 
            "phone": "617-575-7400 or 1-866-330-0326"
        }, 
        "overall_official": {
            "affiliation": "Alnylam Pharmaceuticals", 
            "last_name": "Jared Gollob, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 63 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981837"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK) of ALN-TTRSC (Cmax, tmax, t1/2, AUC, CL, Vss, Vz)", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Effect of ALN-TTRSC on transthyretin (TTR) (Determination of % Lowering of TTR to pretreatment/Baseline Levels)", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }
        ], 
        "source": "Alnylam Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alnylam Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}